A BcfA-containing intranasal vaccine generated TH17 immunity and reduced B. bronchiseptica colonization and disease in mice
Alexa R Aubrey, Komal K Patel, Jesse M Hall, Mohamed M Shamseldin, Myra Guo, Gianni B DeLucia, Siddhi Shah, Kara N Corps, Rajendar Deora, Purnima Dubey · 2026
Read A BcfA-containing intranasal vaccine generated TH17 immunity and reduced B. bronchiseptica colonization and disease in mice by Alexa R Aubrey, Komal K Patel, Jesse M Hall, Mohamed M Shamseldin, Myra Guo, Gianni B DeLucia, Siddhi Shah, Kara N Corps, Rajendar Deora, Purnima Dubey (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13369460.txt.
Description
Alexa Aubrey and nine co-authors test a nose-delivered vaccine in mice in a study from two thousand twenty-six. The target is Bordetella bronchiseptica, a cause of respiratory disease in farm and companion animals. Current vaccines protect briefly and do not build strong mucosal immunity in the airways.
Their vaccine mixes three bacterial proteins, one of which also acts as an adjuvant. Given through the nose, it produced TH17 immune cells in the body and airways, plus antibodies in blood and mucus. Vaccinated mice were protected against weight loss, airway narrowing, and cough after challenge. The bacteria were cleared from the lungs and reduced in the nose. The authors see promise for longer protection in animals.
Catalog record
| CREATOR | Alexa R Aubrey, Komal K Patel, Jesse M Hall, Mohamed M Shamseldin, Myra Guo, Gianni B DeLucia, Siddhi Shah, Kara N Corps, Rajendar Deora, Purnima Dubey |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 32 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |